Cytiva helps Genepeutic Bio install first GMP-certified cell therapy facility in Thailand
- Collaboration will boost capabilities to deliver cancer treatment within Thailand and to Southeast Asia by 2025
- Genepeutic Bio is on track to receive Thai FDA approval for the treatment by end of 2024
August 3, 2023
Cytiva leadership team visit Genepeutic Bio’s manufacturing facility in Thailand
With Cytiva’s FlexFactory biomanufacturing platform, Genepeutic Bio, a leader in Thailand’s life sciences sector, has established the first GMP-certified cell therapy manufacturing facility in Thailand. The 600-square meter facility is located at Innovation Cluster II, Thailand Science Park, Pathum Thani province, Thailand.
Genepeutic Bio aims to bring chimeric antigen receptor-T (CAR T) cell therapies to a few hundred patients with relapsed and refractory blood cancers such as acute lymphoid leukemia (ALL) in Thailand and Southeast Asia by 2025. The company has also applied for Thai Food and Drug Administration (FDA) approval for this treatment and hopes to receive approval by end of 2024.
The research and development of cell and gene therapies, such as CAR T cell therapies, is gaining visibility in Thailand. In late April 2023, Thailand Center of Excellence for Life Sciences (TCELS), the Ministry of Higher Education, Science, Research, and Innovation, the Federation of Thai Industries (FTI), the Board of Trade of Thailand, and the Office of Small and Medium Enterprises Promotion (OSMEP), have announced a combined effort to elevate the life science industry as one of the country’s top growth pillars and propel Thailand to become a high-value medical and health hub.
Dr Parin Rattananon, CEO of Genepeutic Bio, says: “Cytiva’s comprehensive solution solidifies our position as a trusted industry service provider within Thailand and in Southeast Asia. This enhanced manufacturing capability will allow us to meet Thailand’s domestic healthcare demands and bring us one step closer to realizing our vision of providing novel treatment for all.”
Premnath Mandalapu, Commercial General Manager, ASEAN, Cytiva, says: “Developing and manufacturing new therapies requires flexibility, speed, agility, and scale. It also requires having access to GMP (good manufacturing practice) capable engineers to navigate the certification process. Our FlexFactory platform addresses those requirements and is trusted by customers, with more than 100 installations around the world. Now in Thailand for the first time, our FlexFactory will enable Genepeutic Bio to bring the next generation of medicines to patients in Thailand and Southeast Asia who need them most.”
Data from Cytiva’s 2023 Global Biopharma Resilience Index shows that having better access to biopharma talent will facilitate progress in Thailand. 32 percent of respondents in Thailand, compared to the average of 59 percent of respondents globally, are positive about having access to GMP-capable talent.
Cytiva’s FlexFactory biomanufacturing platform includes cell therapy instrumentation, qualification and documentation packages, project management consulting and training services, and the Chronicle automation software platform. It provides an integrated, scalable solution for acceleration and translation to GMP manufacturing, and takes approximately nine months to install and validate.
Read the 2023 Global Biopharma Resilience Index here.
Read more about FlexFactory here.
About Genepeutic Bio
Genepeutic Bio is the first CDMO in Thailand with an R&D department for cell and gene therapy technologies. The company incorporated in 2020, aiming to deliver cell and gene therapy for patients in Thailand and the Asia Pacific region.
The GMP-certified CDMO will manufacture chimeric antigen receptor (CAR) T cell products for patients with relapsed/refractory blood cancers, including acute lymphoid leukemia, diffuse large B-cell lymphoma, and multiple myeloma. The CAR T cell technology is considered a last resource for many cancer patients who failed to respond to conventional treatments such as chemotherapy or targeted therapy. Genepeutic Bio will potentially serve as one of the infrastructures on cell and gene therapy technology for Thailand, which will lead to more accessible treatments to Thai and Asia Pacific patients.
About Cytiva
At Cytiva, our mission is to advance and accelerate the development of therapeutics. With nearly 16 000 associates in more than 40 countries, we’re driven to use our expertise and talent to achieve better flexibility, capacity, and efficiency for our customers. Our broad and deep portfolio of tools and technologies, global scale, and best-in-class service provides critical support from discovery to delivery, for customers spanning researchers, emerging biotech, large-scale biopharma and contract manufacturers.
Learn more at cytiva.com
Media Contact:
Cytiva
Ina Jasni
[email protected]
FlexFactory and Chronicle are trademarks of Global Life Sciences Solutions USA LLC or an affiliate doing business as Cytiva. © 2023 Cytiva.